shire map
Select a

Shire Global


Directorate change

December 4, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following appointments to committees of the Board with effect from December 3, 2015:


Board committee

Steven Gillis2

Audit, Compliance & Risk Committee

David Ginsburg

Nomination Committee

Sara Mathew

Remuneration Committee

1. Each director will serve as a member of the respective Board committee.
2. Dr. Gillis has served as an interim member of the Audit, Compliance & Risk Committee since December 3, 2014.

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations



Matthew Osborne

+1 781 482 9502

Sarah Elton-Farr

+44 1256 894157


Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE